BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Malaguarnera M, Vacante M, Motta M, Giordano M, Malaguarnera G, Bella R, Nunnari G, Rampello L, Pennisi G. Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial. Metab Brain Dis 2011;26:281-9. [DOI: 10.1007/s11011-011-9260-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Palmer LB, Kuftinec G, Pearlman M, Green CH. Nutrition in Cirrhosis. Curr Gastroenterol Rep. 2019;21:38. [PMID: 31289936 DOI: 10.1007/s11894-019-0706-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
2 Sturgeon JP, Shawcross DL. Recent insights into the pathogenesis of hepatic encephalopathy and treatments. Expert Rev Gastroenterol Hepatol. 2014;8:83-100. [PMID: 24236755 DOI: 10.1586/17474124.2014.858598] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
3 Tajiri K, Futsukaichi Y, Kobayashi S, Yasumura S, Takahara T, Minemura M, Sugiyama T. L-Carnitine for the Treatment of Overt Hepatic Encephalopathy in Patients with Advanced Liver Cirrhosis. J Nutr Sci Vitaminol (Tokyo) 2018;64:321-8. [PMID: 30381621 DOI: 10.3177/jnsv.64.321] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
4 Ribas GS, Lopes FF, Deon M, Vargas CR. Hyperammonemia in Inherited Metabolic Diseases. Cell Mol Neurobiol 2021. [PMID: 34665389 DOI: 10.1007/s10571-021-01156-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Martí-carvajal AJ, Gluud C, Arevalo-rodriguez I; Cochrane Hepato-Biliary Group. Acetyl-L-carnitine for patients with hepatic encephalopathy. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd011451] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Abu Ahmad N, Armaly Z, Berman S, Jabour A, Aga-mizrachi S, Mosenego-ornan E, Avital A. l-Carnitine improves cognitive and renal functions in a rat model of chronic kidney disease. Physiology & Behavior 2016;164:182-8. [DOI: 10.1016/j.physbeh.2016.05.036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
7 Ceccarelli M, Rullo EV, Condorelli F, Vitale F, Marco VD, Nunnari G, Pellicanò GF. Unusual Signs and Symptoms in HIV-Positive Patients Coinfected with Leishmania spp: The Importance of Neglected Tropical Disease in Differential Diagnosis. Open Access Maced J Med Sci 2018;6:843-7. [PMID: 29875857 DOI: 10.3889/oamjms.2018.186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
8 Abbasnezhad A, Choghakhori R, Kashkooli S, Alipour M, Asbaghi O, Mohammadi R. Effect of L-carnitine on liver enzymes and biochemical factors in hepatic encephalopathy: A systematic review and meta-analysis. J Gastroenterol Hepatol 2019;34:2062-70. [PMID: 31254469 DOI: 10.1111/jgh.14765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
9 Jamilian H, Jamilian M, Samimi M, Afshar Ebrahimi F, Rahimi M, Bahmani F, Aghababayan S, Kouhi M, Shahabbaspour S, Asemi Z. Oral carnitine supplementation influences mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Gynecol Endocrinol 2017;33:442-7. [PMID: 28277138 DOI: 10.1080/09513590.2017.1290071] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
10 Ribas GS, Vargas CR, Wajner M. L-carnitine supplementation as a potential antioxidant therapy for inherited neurometabolic disorders. Gene. 2014;533:469-476. [PMID: 24148561 DOI: 10.1016/j.gene.2013.10.017] [Cited by in Crossref: 120] [Cited by in F6Publishing: 110] [Article Influence: 13.3] [Reference Citation Analysis]
11 Khungar V, Poordad F. Management of overt hepatic encephalopathy. Clin Liver Dis. 2012;16:73-89. [PMID: 22321466 DOI: 10.1016/j.cld.2012.03.009] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
12 Hanai T, Shiraki M, Imai K, Suetugu A, Takai K, Shimizu M. Usefulness of Carnitine Supplementation for the Complications of Liver Cirrhosis. Nutrients 2020;12:E1915. [PMID: 32610446 DOI: 10.3390/nu12071915] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Koziarska D, Wunsch E, Milkiewicz M, Wójcicki M, Nowacki P, Milkiewicz P. Mini-Mental State Examination in patients with hepatic encephalopathy and liver cirrhosis: a prospective, quantified electroencephalography study. BMC Gastroenterol 2013;13:107. [PMID: 23815160 DOI: 10.1186/1471-230X-13-107] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
14 Martí-Carvajal AJ, Gluud C, Arevalo-Rodriguez I, Martí-Amarista CE. Acetyl-L-carnitine for patients with hepatic encephalopathy. Cochrane Database Syst Rev 2019;1:CD011451. [PMID: 30610762 DOI: 10.1002/14651858.CD011451.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
15 Sato S, Namisaki T, Furukawa M, Saikawa S, Kawaratani H, Kaji K, Takaya H, Shimozato N, Sawada Y, Kitagawa K, Moriya K, Akahane T, Mitoro A, Hoki N, Ann T, Yoshiji H. Effect of L-carnitine on health-related quality of life in patients with liver cirrhosis. Biomed Rep 2020;13:65. [PMID: 33149909 DOI: 10.3892/br.2020.1372] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
16 Shiraki M, Shimizu M, Moriwaki H, Okita K, Koike K. Carnitine dynamics and their effects on hyperammonemia in cirrhotic Japanese patients. Hepatol Res 2017;47:321-7. [PMID: 27254133 DOI: 10.1111/hepr.12750] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
17 Ferro JM, Viana P, Santos P. Management of Neurologic Manifestations in Patients with Liver Disease. Curr Treat Options Neurol 2016;18:37. [PMID: 27314429 DOI: 10.1007/s11940-016-0419-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
18 Li N, Zhao H. Role of Carnitine in Non-alcoholic Fatty Liver Disease and Other Related Diseases: An Update. Front Med (Lausanne) 2021;8:689042. [PMID: 34434943 DOI: 10.3389/fmed.2021.689042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Malaguarnera M. Carnitine derivatives: clinical usefulness. Curr Opin Gastroenterol 2012;28:166-76. [PMID: 22333562 DOI: 10.1097/MOG.0b013e3283505a3b] [Cited by in Crossref: 64] [Cited by in F6Publishing: 28] [Article Influence: 6.4] [Reference Citation Analysis]
20 Pennisi M, Lanza G, Cantone M, D'Amico E, Fisicaro F, Puglisi V, Vinciguerra L, Bella R, Vicari E, Malaguarnera G. Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. Nutrients 2020;12:E1389. [PMID: 32408706 DOI: 10.3390/nu12051389] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
21 Acharya C, Bajaj JS. Current Management of Hepatic Encephalopathy. Am J Gastroenterol. 2018;113:1600-1612. [PMID: 30002466 DOI: 10.1038/s41395-018-0179-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
22 Pirmadah F, Ramezani-Jolfaie N, Mohammadi M, Talenezhad N, Clark CCT, Salehi-Abargouei A. Does L-carnitine supplementation affect serum levels of enzymes mainly produced by liver? A systematic review and meta-analysis of randomized controlled clinical trials. Eur J Nutr 2020;59:1767-83. [PMID: 31385062 DOI: 10.1007/s00394-019-02068-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
23 Yousefi Rad E, Eslampour E, Falahi E, Mardani M, Hekmatdoost A, Asbaghi O, Saboori S. Effects of carnitine supplementation on liver aminotransferase enzymes: A systematic review and meta-analysis of randomized controlled clinical trials. Indian J Gastroenterol 2019;38:470-9. [PMID: 31828538 DOI: 10.1007/s12664-019-00983-2] [Reference Citation Analysis]
24 Alimirah M, Sadiq O, Gordon SC. Novel Therapies in Hepatic Encephalopathy. Clin Liver Dis 2020;24:303-15. [PMID: 32245535 DOI: 10.1016/j.cld.2020.01.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Khungar V, Poordad F. Hepatic encephalopathy. Clin Liver Dis. 2012;16:301-320. [PMID: 22541700 DOI: 10.1016/j.cld.2011.12.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
26 Amodio P. Hepatic encephalopathy. In: Lee SS, Moreau R, editors. Cirrhosis: A practical guide to management. Chichester: John Wiley & Sons, Ltd; 2015. pp. 105-23. [DOI: 10.1002/9781118412640.ch11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Cuturic M, Abramson RK, Moran RR, Hardin JW, Frank EM, Sellers AA. Serum carnitine levels and levocarnitine supplementation in institutionalized Huntington’s disease patients. Neurol Sci. 2013;34:93-98. [PMID: 22294053 DOI: 10.1007/s10072-012-0952-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
28 Frontera JA. Management of hepatic encephalopathy. Curr Treat Options Neurol. 2014;16:297. [PMID: 24807164 DOI: 10.1007/s11940-014-0297-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
29 Pennisi M, Lanza G, Cantone M, D'Amico E, Fisicaro F, Puglisi V, Vinciguerra L, Bella R, Vicari E, Malaguarnera G. Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. Nutrients 2020;12:E1389. [PMID: 32408706 DOI: 10.3390/nu12051389] [Reference Citation Analysis]
30 Malaguarnera M. Acetyl-L-carnitine in hepatic encephalopathy. Metab Brain Dis 2013;28:193-9. [DOI: 10.1007/s11011-013-9376-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
31 López-Franco Ó, Morin JP, Cortés-Sol A, Molina-Jiménez T, Del Moral DI, Flores-Muñoz M, Roldán-Roldán G, Juárez-Portilla C, Zepeda RC. Cognitive Impairment After Resolution of Hepatic Encephalopathy: A Systematic Review and Meta-Analysis. Front Neurosci 2021;15:579263. [PMID: 33790729 DOI: 10.3389/fnins.2021.579263] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Chokshi S. Can we reliably predict response to corticosteroid treatment in severe alcoholic hepatitis? Hepatol Commun 2018;2:625-7. [PMID: 29881814 DOI: 10.1002/hep4.1191] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
33 Bortolato B, Miskowiak KW, Köhler CA, Maes M, Fernandes BS, Berk M, Carvalho AF. Cognitive remission: a novel objective for the treatment of major depression? BMC Med 2016;14:9. [PMID: 26801406 DOI: 10.1186/s12916-016-0560-3] [Cited by in Crossref: 104] [Cited by in F6Publishing: 92] [Article Influence: 17.3] [Reference Citation Analysis]
34 Kou L, Sun R, Ganapathy V, Yao Q, Chen R. Recent advances in drug delivery via the organic cation/carnitine transporter 2 (OCTN2/SLC22A5). Expert Opin Ther Targets 2018;22:715-26. [PMID: 30016594 DOI: 10.1080/14728222.2018.1502273] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
35 Malaguarnera G, Catania VE, Bonfiglio C, Bertino G, Vicari E, Malaguarnera M. Carnitine Serum Levels in Frail Older Subjects. Nutrients 2020;12:E3887. [PMID: 33352627 DOI: 10.3390/nu12123887] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Hiramatsu A, Aikata H, Uchikawa S, Ohya K, Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, Honda F, Inagaki Y, Morio K, Morio R, Fujino H, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Imamura M, Tanaka J, Chayama K. Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis. Hepatol Commun 2019;3:348-55. [PMID: 30859147 DOI: 10.1002/hep4.1309] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
37 Jiang Q, Jiang G, Shi K, Cai H, Wang Y, Zheng M. Oral Acetyl-L-Carnitine treatment in hepatic encephalopathy: view of evidence-based medicine. Annals of Hepatology 2013;12:803-9. [DOI: 10.1016/s1665-2681(19)31323-7] [Cited by in Crossref: 24] [Article Influence: 2.7] [Reference Citation Analysis]
38 Mescka CP, Guerreiro G, Donida B, Marchetti D, Wayhs CA, Ribas GS, Coitinho AS, Wajner M, Dutra-Filho CS, Vargas CR. Investigation of inflammatory profile in MSUD patients: benefit of L-carnitine supplementation. Metab Brain Dis 2015;30:1167-74. [PMID: 26002427 DOI: 10.1007/s11011-015-9686-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
39 Askarpour M, Djafarian K, Ghaedi E, Sadeghi O, Sheikhi A, Shab-bidar S. Effect of L-Carnitine Supplementation on Liver Enzymes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Archives of Medical Research 2020;51:82-94. [DOI: 10.1016/j.arcmed.2019.12.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Wang AG, Diamond M, Waddell J, McKenna MC. Effect of Acetyl-L-carnitine Used for Protection of Neonatal Hypoxic-Ischemic Brain Injury on Acute Kidney Changes in Male and Female Rats. Neurochem Res 2019;44:2405-12. [PMID: 31041669 DOI: 10.1007/s11064-019-02807-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]